Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBIT (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed EBIT for 16 consecutive years, with -$39.8 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 11.45% to -$39.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$113.6 million through Dec 2025, down 24.95% year-over-year, with the annual reading at -$113.6 million for FY2025, 24.95% down from the prior year.
  • EBIT hit -$39.8 million in Q4 2025 for Perspective Therapeutics, down from -$27.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.3 million in Q2 2021 to a low of -$45.0 million in Q4 2024.
  • Historically, EBIT has averaged -$12.9 million across 5 years, with a median of -$9.8 million in 2023.
  • Biggest five-year swings in EBIT: surged 213.2% in 2021 and later crashed 998.4% in 2023.
  • Year by year, EBIT stood at -$1.6 million in 2021, then skyrocketed by 34.98% to -$1.1 million in 2022, then plummeted by 998.4% to -$11.7 million in 2023, then plummeted by 285.27% to -$45.0 million in 2024, then rose by 11.45% to -$39.8 million in 2025.
  • Business Quant data shows EBIT for CATX at -$39.8 million in Q4 2025, -$27.9 million in Q3 2025, and -$24.0 million in Q2 2025.